Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients

BACKGROUND: Nintedanib is a clinically approved multikinase receptor inhibitor to treat non-small cell lung cancer with adenocarcinoma (ADC) histology in combination with docetaxel, based on the clinical benefits reported on ADC but not on squamous cell carcinoma (SCC), which are the two most common...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabasa, M, Ikemori, R, Hilberg, F, Reguart, N, Alcaraz, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674098/
https://www.ncbi.nlm.nih.gov/pubmed/28898237
http://dx.doi.org/10.1038/bjc.2017.270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674098/
https://www.ncbi.nlm.nih.gov/pubmed/28898237
http://dx.doi.org/10.1038/bjc.2017.270

Ejemplares similares